It’s 2021 & covid-19 vaccines, will this pandemic really end?

Several highly effective Covid-19 vaccines are now being administered across Indonesia, and more are in the pipeline.

Indonesian citizens are waiting in line to get shot of these vaccines, and we are waiting for announcement of officials immunize by the President of Indonesia. Vaccines are critical in drawing down the pandemic as we know it, but it won’t be a simple return to the world before Covid-19.

It will likely be a process that lasts several months, and precautions like social distancing and wearing masks will still be needed until there is widespread immunity to the virus. “It’s a bit of a glide path in my mind toward a new normal, and a new normal that will continue to get better and better,” said Ashish Jha, dean of the School of Public Health at Brown University. “Ultimately, the mental model that I’m going for is ‘When are people going about their day and not thinking about Covid?’”

Exactly when and how this will happen hinges on several key variables relating to vaccines that scientists and health officials are still trying to sort out. The vaccines being administered right now have only received emergency use authorizations, not full approval, from the Food and Drug Administration.

Regulators have determined that the benefits of the vaccine outweigh the risks for most adults at high risk of exposure, but there are still some unanswered questions, such as how long protection lasts and how well these vaccines block transmission of the virus between people. And beyond the vaccines themselves, how quickly and how readily people accept them can change the course of the pandemic.

How well a Covid-19 vaccine contains the pandemic depends on the answers to several key questions. The clinical trials for Covid-19 vaccines are still ongoing, and more clarity will emerge in the coming months. But for now, these remain some of the most important unknowns.

How well do vaccines prevent the spread of SARS-CoV-2? Both the Moderna vaccine and the Pfizer/BioNTech vaccine reported efficacies of roughly 95 percent against Covid-19 disease, meaning they protected the vast majority of recipients from getting sick enough to have disease symptoms, like loss of smell, fever, and cough. However, Covid-19 is caused by a virus, SARS-CoV-2, that some people can carry and transmit without having any symptoms at all — whether or not they eventually end up feeling ill.

Finding the people who are carrying the virus (and preventing them from infecting others) is therefore critical to control the spread of the virus, but has proven to be a persistent obstacle during the pandemic. Currently, the main way to identify the infected is by proactively testing for the virus and, ideally, tracing who else they encountered. It’s a tedious, time-consuming process. This is also true in vaccine clinical trials. Phase 3 trials mainly look at how well vaccines prevent disease in the real world, something that’s readily apparent when comparing the number of disease events in the vaccine group to the placebo group. It only takes 150 events or so to yield results on how well the vaccine prevents disease.

But to gauge efficacy against preventing infections, including low-grade infections that don’t generate symptoms, researchers will have to test the tens of thousands of participants in their phase 3 trial. It’s likely that a Covid-19 vaccine would reduce transmission, but it’s not clear yet by how much. “What we know is that we’ve been seeing studies focusing specifically on efficacy with regards to severity of disease, meaning ameliorating the severity of the disease itself, but there’s still no studies that really are going to help us understand how we can certainly interrupt transmission,” said Maria Elena Bottazzi, a co-director of the Texas Children’s Hospital Center for Vaccine Development.

The companies conducting trials do plan to test their participants to see if there were any hidden infections, but it may be a while before they report their results. That said, Moderna presented some early data showing that its vaccine does begin to reduce infections between its doses, which are spaced 28 days apart. “There were approximately 2/3 fewer swabs that were positive in the vaccine group as compared to the placebo group at the pre-dose 2 timepoint, suggesting that some asymptomatic infections start to be prevented after the first dose,” according to Moderna’s report to the FDA. However, these results are preliminary and will require follow-up testing to see if this effect lasts longer than a few weeks.

The more that a vaccine can reduce the virus’s transmission, the more quickly a population can move toward herd immunity, the point where the virus can no longer spread easily between people. Scientists estimate that herd immunity threshold is when roughly between 60 percent and 90 percent of a population is immune to this virus, whether through a vaccine or from natural exposure. (A recent study in the New England Journal of Medicine showed that health workers in the United Kingdom exposed to SARS-CoV-2 produced protective antibodies against the virus and were protected against reinfection for at least six months. But vaccines might not protect every single person who gets a shot from getting infected, just like they don’t provide a 100 percent guarantee against getting sick. That means even the vaccinated will still have to wear face masks and keep their distance from others to prevent virus transmission until immunity is widespread.

How long do vaccines protect against Covid-19? The Moderna and Pfizer/BioNTech trials have shown that their vaccines start to provide protection against Covid-19 illness quickly — and that protection starts building up right after the first dose. Whether that protection fades after a few months or a few years is unclear. And researchers can only find out by waiting and observing. That means monitoring the thousands of participants of clinical trials, as well as recipients of the vaccines in the general population, for years. Pfizer and BioNTech, as well as Moderna, have committed to actively monitoring the participants in their clinical trials for at least two years. They are also keeping an eye on people who are receiving their vaccines.

But hints on the durability of vaccine protection could arrive sooner. Looking at vaccine recipients six months or one year after they receive their injections, researchers should be able to see how many were infected with SARS-CoV-2 — and when — to get an early estimate of how quickly protection weakens. “That would give us potentially some information for what future years will look like,” said Meagan Fitzpatrick, an assistant professor at the center for vaccine development and global health at the University of Maryland School of Medicine. “You will definitely get some signal, but you don’t know really for sure in a way that’s backed up by data until that amount of time passes from when the first people got their first doses.” Longer protection would buy time for the health sector as vaccines roll out since they wouldn’t have to worry about reinfections or revaccinating people. Evidence from past coronavirus outbreaks like SARS and MERS showed that among survivors, protection for those diseases lasted for several years. But SARS-CoV-2 is a new virus, and much remains uncertain.

There’s also a chance that SARS-CoV-2 could mutate in a way that would escape the protection offered by a vaccine. However, scientists say that’s unlikely in the near term because Covid-19 vaccines target several different parts of the virus and the odds of simultaneous mutations in all of those regions are low. But more study is needed to yield more definite answers, and the best way to reduce the likelihood of major mutations in SARS-CoV-2 is to limit its spread.

How quickly can we get the vaccine to everyone? The United States is now in the midst of its largest vaccination campaign in history, an endeavor that’s anywhere from three to four times as big as vaccinating against seasonal flu, according to Moncef Slaoui, the scientific lead for the Department of Health and Human Services’ Operation Warp Speed vaccine program. It’s a delicate and critical process. “How soon can we really start driving our Covid numbers low really definitely depends on rollout,” Fitzpatrick said. “A vaccine is only as good as the doses that actually get into people.”

However, the debut of Covid-19 vaccines has already hit several bumps. Some states have reported that their initial allotments of the Pfizer/BioNTech vaccine were cut, while the manufacturer reported that many doses have gone unclaimed. Part of the challenge is technical constraints of the vaccines themselves. Both the Moderna and the Pfizer/BioNTech vaccines require maintaining cold temperatures from factories to transportation to clinics. The Pfizer/BioNTech vaccine in particular demands ultra-cold storage at temperatures of minus 70 degrees Celsius (minus 94 degrees Fahrenheit).

We still need testing, masking, distancing, and treatments. While scientists and health experts have been elated at the speed at which Covid-19 vaccines have been developed, they’ve also been adamant that vaccines on their own are not enough to control the Covid-19 pandemic. The existing measures for slowing Covid-19 remain just as important as they’ve ever been, if not more so, given that hospitalizations and daily deaths are continuing to mount.

Tactics like wearing face masks, rigorous hand-washing, and avoiding large gatherings and close contact with others will still be needed in the coming months, even among people who have been immunized. Treatments for Covid-19 are also critical since they are the most immediate way to reduce fatalities. Approaches like monoclonal antibodies will be needed to help people survive the illness. Widespread testing for Covid-19 will also continue to be crucial to identify potential spreaders and to allow people in key jobs to continue working.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
en_USEnglish